Objective To observe the clinical efficacy and security of oxycodone hydrochloride controlledrelease tablets combined with fluvoxamine in treating moderate and severe cancer pain complicated with depression.Methods One hundred and twenty patients with moderate and severe cancer pain complicated with depression from January 2013 to September 2014 were randomly divided into control group given oxycodone hydrochloride controlled-release tablets (titrating dosage) and observation group given oxycodone hydrochloride controlled-release tablets (titrating dosage) and fluvoxamine (first dose 50 mg/time,increased by 50-100 mg next day,≤300 rg/d).The pain numerical rating scale (NRS) score,self-rating depression scale (SDS) score,incidence of adverse reactions 4 weeks after treatment were compared between groups.Results After treatment,the NRS score and SDS score in observation group were significantly lower than those in control group [(1.5 ± 1.1) scores vs (2.1 ±1.1) scores,(42 t 7) scores vs (46 ± 8) scores] (P ＜ 0.05).The incidence of constipation in observation group was significantly lower than that in control group [31.7 ％ (19/60) vs 51.7 ％ (31/60)] (P ＜ 0.05),the incidences of other adverse effects were not significantly different between groups (P ＞ 0.05).Conclusion Fluvoxamine combined oxycodone hydrochloride controlled-release tablets can effectively control the cancer pain,relieve the symptom of depression,and reduce the adverse reactions induced by oxycodone hydrochloride controlled-release tahlets.

目的 比较奥沙利铂联合替吉奥(SOX方案)和吉西他滨联合顺铂(GP方案)治疗晚期三阴性乳腺癌的疗效和不良反应.方法 晚期三阴性乳腺癌患者随机分别接受多周期SOX方案(SOX组,63例)和GP方案(GP组,57例)化疗.评价两组疗效和不良反应.结果 SOX组与GP组的总有效率(RR)分别为34.9％与35.1％,疾病控制率(DCR)为68.3％与70.2％,差异无统计学意义(P＞0.05);中位进展时间分别为9.5月与8.1月,差异有统计学意义(P=0.033);1年生存率分别为69.8％和63.2％,总生存时间(OS)分别为19.5月与18.7月,差异无统计学意义(P=0.554、0.207).常见的不良反应相似,其中腹泻、肝功能损害、外周神经毒性和手足综合征发生率SOX组明显高于GP组,血小板减少、恶心/呕吐、肾毒性和皮疹发生率GP组明显高于SOX组(P＜0.05).结论 奥沙利铂联合替吉奥、吉西他滨联合顺铂方案治疗晚期三阴性乳腺癌均安全、有效,不良反应耐受.

Objective To observe clinical efficacy and safety on the treatment of moderate-severe cancer pain by Fluvoxamine combined with Oxycodone. Methods 120 cancer patients with moderate pain and 120 cases with severe pain were selected, randomly divided into experimental group and control group. The control group were given oxycodone alone , and experimental group given fluvoxamine combined with oxycodone , till the pain relieved, then the degree of pain relief, oxycodone dosage, life quality and side effects were evaluated. Results The degree of pain relief in experimental group were much better than control group (P < 0.05). Oxycodone consumption were lower in experimental group than control group , and the difference was no significant difference in controlling moderate pain (P = 0.065), while statistically significant in controlling severe pain (P = 0.035). The general status, daily activity, mood, and sleep affected by cancer pain were released after treatment, especially in experimental group (P < 0.05). The most common side effects were approximative, and the incidence of constipation, nausea/vomiting, lethargy were lower in experimental group than control group (P =0.026). Conclusion Fluvoxamine combined with Oxycodone can effectively control moderate-severe cancer pain, and reduce the oxycodone dosage and some side effects, and therefore, improve the quality of life.

Objective:To investigate procalcitonin and C-reactive protein levels in diarrheal patients who underwent irinotecan che-motherapy. Methods:Procalcitonin and C-reactive protein were detected among 85 diarrheal and 63 non-diarrheal patients after irinote-can chemotherapy. Results:According to WHO classification, patients without diarrhea are classified as grade 0, whereas patients with diarrhea can be classified as gradesⅠ-Ⅳ. In grades 0,Ⅰ,Ⅱ,Ⅲ, andⅣpatients, the levels of procalcitonin were 0.29 ± 0.17, 0.30 ± 0.18, 0.36 ± 0.20, 1.24 ± 0.22, and 2.15 ± 0.26 ng/mL on the second day, respectively. However, on the fourth day, the procalcitonin lev-els were 0.28 ± 0.15, 0.30 ± 0.14, 0.34 ± 0.18, 2.00 ± 0.22, and 2.40 ± 0.28 ng/mL, respectively. Moreover, in grades 0,Ⅰ,Ⅱ,Ⅲ, andⅣ, the levels of C-reactive protein were 6.06 ± 1.85, 6.12 ± 1.16, 6.20 ± 1.68, 22.62 ± 4.55, and 31.26 ± 5.23 mg/L on the second day, respectively. On the fourth day, the C-reactive protein levels were 5.80 ± 1.82, 5.94 ± 1.14, 6.15 ± 1.55, 30.52 ± 4.74, and 38.67 ± 5.68 mg/L, respectively. No significant difference was found between the procalcitonin and C-reactive protein levels of stagesⅠandⅡpa-tients (P>0.05), but a significant difference was found between stagesⅠ, andⅡpatients and stagesⅢandⅣpatients (P<0.05). Con-clusion: Monitoring levels of procalcitonin and C-reactive protein may be helpful in the early evaluation of the severity of diarrhea. This process has prognostic effect and can be used to assess whether patients have enterogenous bacterial infection. Monitoring the lev-els of these proteins has certain clinical value and can be used to guide early anti-infection therapy.

目的:评价文拉法辛联合盐酸吗啡缓释片治疗中、重度癌性疼痛患者的镇痛效果和药物不良反应. 方法:将中、重度癌痛122例患者随机分组,其中62例予以文拉法辛联合盐酸吗啡缓释片(试验组),60例予以盐酸吗啡缓释片治疗(对照组),评价两组疗效和副反应. 结果:两组用药后疼痛强度、中度以上疼痛缓解率第一天、第二天、第三天差异有显著性(P < 0.05),第四天及以后差异无显著性(P > 0.05),试验组优于对照组. 平均维持剂量、 平均最大剂量及达到维持剂量平均时间试验组与对照组分别为 57.5 mg/d vs 80.4 mg/d、59.0 mg/d vs 80.7 mg/d、1.4 h vs 1.9 h,两组差异有统计意义(均P < 0.05). 消化道反应试验组优于对照组(27.4% vs 53.3%)(P < 0.05). 结论:文拉法辛联合吗啡治疗癌性疼痛缓解率高,吗啡剂量减少,副反应少.

Objective To explore the expression of trefoil factor family 1(TFF1) in colorectal carcinoma.Methods Collecting the specimens of normal colorectal,colorectal adenoma,colorectal adenocarcinoma and colorectal carcinoma tissue and measuring the expression of TFF1 by S-P.Results TFF1 was not expressed in the normal colorectal tissue,it began to express in the tissue of colorectal adenoma and adenocarcinoma,and clearly expressed in the colorectal carcinoma tissue.It showed significant difference(P0.05).the expression of TFF1 showed significant relationship with Dukes,degree of tumour differentiation(P0.05),and no relationship with metastasis of lymph(P0.05).Conclusion TFF1 highly expression in the tissue of colorectal adenoma and colorectal carcinoma suggests that TFF1 may play a certain role in the occurrence and development of colorectal carcinoma.

结肠直肠癌是常见的消化道恶性肿瘤.近20年来,其发病率明显上升,因此诊断和病情评估具有十分重要的意义.

目的:观察重组人白细胞介素-11对化疗后口腔粘膜炎的疗效.方法:对64例化疗后出现口腔粘膜炎患者随机分为两组,治疗组接受重组人白细胞介素-11吉巨芬治疗(32例),对照组接受接受常规治疗(32例).结果:治疗结束时评价显效、好转和无效的治疗组患者分别为9例,16例和7例,治疗组总有效率达78.1%,较对照组有显著性差异(P＜0.01).结论:使用重组人白细胞介素-11治疗化疗后口腔粘膜炎是有效和安全的.

食管癌是我国常见恶性肿瘤,居恶性肿瘤的第4位,在某些高发区居第1位[1], 严重威胁我国人民的健康和生命.食管癌预后差,5年生存率10%～20%, 有50%～60%的患者就诊时已有远处转移,中位生存期4～8个月.为探索晚期食管癌的有效化疗方案,作者对本院2006年6月～2008年5月26例晚期食管癌,采用TCF[紫杉醇脂质体(力扑素)联合顺铂、5-氟脲嘧啶]方案化疗,取得了较好的疗效,现总结报告如下.